通过导管关闭心房 Septal 缺陷: 目前使用的设备的审查
Shitij Shrivastava1, Shashwat Shrivastava2, Sai Vishnu Vardhan Allu1
1Internal Medicine, BronxCare Health System, New York, USA.
Cureus
|July 10, 2023
概括
使用FDA批准的设备,通过导管关闭心房隔膜缺陷 (ASD) 和形孔 (PFO) 是安全有效的. 与手术相比,这些设备的成功率很高,降低了中风风险,并缩短了住院时间.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 医疗器械技术 医疗器械技术
背景情况:
- 在过去的七十年中,心房隔膜缺陷 (ASD) 和圆孔 (PFO) 的穿皮关闭已经显著发展.
- 目前在美国有三种FDA批准的设备:阿姆普拉特泽隔膜封闭器 (ASO),阿姆普拉特泽形封闭器和戈尔心脏形ASD封闭器.
研究的目的:
- 审查FDA批准的ASD和PFO关闭的跨导管装置的当前文献.
- 评估与这些设备相关的安全性,有效性和结果.
主要方法:
- 临床研究和对阿姆普拉特泽 Septal Occluder,阿姆普拉特泽Cribriform Occluder和戈尔心脏形ASD Occluder的元分析的综述.
- 分析来自RESPECT,ASD PMS II和REDUCE等试验的数据.
- 通过导管关闭与手术关闭的比较以及报告的并发症的评估.
主要成果:
- ASO在ASD关闭方面表现出高的成功率,并在PFO关闭方面降低了中风风险 (RESPECT试验).
- 阿姆普拉特泽Cribriform Occluder显示出对多窗自闭症的治疗有希望.
- 戈尔心形ASD Occluder表现出卓越的性能,成功率高,并发症率低 (保证研究).
- 过导管关闭与高成功率,较少的不良事件和比手术更短的住院时间有关.
- 报告的并发症虽然很少见,但包括器件栓塞,侵蚀和新发的偏头痛.
结论:
- 使用FDA批准的设备关闭跨导管ASD和PFO是安全有效的治疗选择.
- 这些设备提供了显著的好处,包括高的关闭率和降低复发性中风的风险.
- 仔细的患者选择和勤奋的随访对于优化结果和最大限度地减少潜在的并发症至关重要.
关键词:
安普拉泽尔cribriform封闭器封闭器放大器隔膜阻塞器 阻塞器遗传性心脏病是一种心脏病.伤的心脏形隔膜封闭器干预性心脏病学 干预性心脏病学奥斯二次心房隔膜缺陷专利 形圆形孔穿皮性心房隔膜缺陷闭塞闭塞通过皮肤的pfo闭合.通过导管的关闭装置.更多相关视频
08:00Reduction of Iatrogenic Atrial Septal Defects with an Anterior and Inferior Transseptal Puncture Site when Operating the Cryoballoon Ablation Catheter
Published on: June 15, 2015
14.0K
23:33The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
83.7K
相关概念视频
01:25Mitral Regurgitation III: Medical Management
19
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
19
01:25Aortic Regurgitation III: Medical Management
26
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
26
01:26Mitral Stenosis III: Medical Management
13
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
13